Drug Trial Radar · NCT06918002
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
824
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
May 2036
Study completion May 2036
Sponsor
- Lead sponsor
- Intergroupe Francophone du MyelomeResearch network
- Sponsor type
- Research network
- Collaborators
- Pfizer
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT. 824 patients will be enrolled in this study from approximately 70 study sites. The 2 parts in the Treatment Phase are described below. Part 1: Induction/ASCT/Consolidation Phase (1:1 Randomization) After the screening period, patients will be randomly allocated (1:1) to either: * Arm A (standard of care arm): standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, D-VRd consolidation therapy * Arm B (experimental arm): standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy. Part 2: Maintenance Phase (1:1 Re-randomization) Patients will be re-randomized (1:1) and will enter the Maintenance Phase upon completion of consolidation therapy. • Arm C (standard of care arm): daratumumab + lenalidomide approx 2 years. Subjects with a negative MRD (for at least 12 months) after 24 cycles of daratumumab-lenalidomide will discontinue daratumumab and continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first). Subjects who did not achieve MRD negativity for at least 12 months after 24 cycles of daratumumab-lenalidomide will continue to receive daratumumab-lenalidomide until: * MRD negativity for at least 12 months is reached. Subjects will then continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first). * Disease progression * Or study cut-off date (whichever occurs first). * Arm D (experimental arm): elranatamab. Approx 2 years. Subjects with a negative MRD (for at least 12 months) after receiving M22 administration of elranatamab will discontinue study treatment with elranatamab. Subjects who did not achieve MRD negativity for at least 12 months after M22 elranatamab administration will continue to receive elranatamab, every 24 weeks, until MRD negativity for at least 12 months is reached, disease progression, or study cut-off date (whichever occurs first).
Conditions
- Multiple Myeloma, Newly Diagnosed
Interventions
ElranatamabDrug
Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms
Lenalidomide (Revlimid®)Drug
In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C)
Daratumumab SC (Darzalex)Drug
Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A
Autologous Stem Cell TransplantationProcedure
ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD
Bortezomib (Velcade®)Drug
Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A
DexamethasoneDrug
Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (induction/consolidation) from Randomization 1 (R1): to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Minimal Residual Disease (MRD) negativity rateTime frame: at end of consolidation, up to 36 months
- Part 2 (maintenance) from Randomization 2 (R2): to assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of Progression Free Survival (PFS).Time frame: from the date of second randomization to the date of confirmed PD (IMWG criteria,) or death from any cause, whichever came first, assessed up to 93 monts
- Key secondary objectives: Part 1 (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFSTime frame: PFS defined as the time interval from the date of first randomization to the date of confirmed Progression Disease (IMWG criteria) or death from any cause, whichever occurs first., assessed up to 128 months
- Key secondary objectives: Part I (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Overal Survival (OS)Time frame: up to 128 months
Locations
69 sites in 2 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium · Not yet recruiting
Cliniques Universitaires Saint Luc
Brussels, Belgium · Not yet recruiting
Grand Hopital Charleroi
Charleroi, Belgium · Not yet recruiting
CHU de Liège
Liège, Belgium · Not yet recruiting
CHU UCL Namur
Yvoir, Belgium · Not yet recruiting
CHU Amiens
Amiens, France · Recruiting
CHU Angers
Angers, France · Recruiting
Ch Annecy Genevois
Annecy, France · Recruiting
Centre Hospitalier d'Argenteuil Victor Dupouy
Argenteuil, France · Recruiting
Centre Hospitalier H. Duffaut
Avignon, France · Recruiting
Centre hospitalier de la Côte Basque
Bayonne, France · Recruiting
CHU Besançon
Besançon, France · Recruiting
Centre Hospitalier Simone Veil
Blois, France · Recruiting
Hôpital Avicenne
Bobigny, France · Recruiting
CHU Bordeaux - Hopital Haut Lévêque - Centre F. Magendi
Bordeaux, France · Recruiting
CH Fleyriat
Bourg-en-Bresse, France · Recruiting
CHRU Brest - Hôpital A. Morvan
Brest, France · Recruiting
CHU Caen - Côte de Nacre
Caen, France · Recruiting
Centre Hospitalier William Morey
Chalon-sur-Saône, France · Recruiting
CHMS Centre Hospitalier Métropole Savoie
Chambéry, France · Recruiting
Hopital Louis Pasteur
Chartres, France · Recruiting
Hôpital d'Instruction des Armées Percy
Clamart, France · Recruiting
Chu Estaing
Clermont-Ferrand, France · Recruiting
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France · Recruiting
CHU Henri Mondor
Créteil, France · Recruiting
CHU Dijon
Dijon, France · Recruiting
Institut de cancérologie de Bourgogne
Dijon, France · Recruiting
Centre Hospitalier de Dunkerque
Dunkirk, France · Recruiting
CHU de Grenoble
Grenoble, France · Recruiting
CHU de la Réunion Site SUD (Terre Sainte)
La Réunion, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
Hopital Monod
Le Havre, France · Recruiting
CH Le mans
Le Mans, France · Recruiting
CHRU Hôpital Claude Huriez
Lille, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Limoges
Limoges, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Centre Hospitalier Lyon Sud
Lyon, France · Recruiting
Grand Hopital Est Francilien (GHEF) Site de Meaux
Meaux, France · Recruiting
Hôpital de Mercy (CHR Metz-Thionville)
Metz, France · Recruiting
Centre de Recherche Clinique / GHT des Landes
Mont-de-Marsan, France · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.